

Press release from Emotra AB (publ)
Göteborg, November 25, 2021

EMOTRA AB: Our dispute with an Italian supplier has finally been resolved

Emotra is happy to announce that a dispute with an Italian supplier that has been ongoing since 2017 has finally been resolved.

As we have previously communicated, for example in Emotra AB's annual reports for the years 2017–2020, we have been locked in a dispute with an Italian supplier since 2017. The dispute concerns a claim amounting to approximately 1.7 MSEK, plus certain interest charges. For this reason, Emotra AB has set aside about SEK 800,000 in our books, accounting for them as payables and accrued costs, to make provision for the payment obligation that may be established upon resolution of the dispute.

A lawsuit in this dispute was filed at the district court of Göteborg in May, 2020. The main hearing was scheduled to take place during a few days at the end of November 2021. Shortly before the hearing, though, the parties reached a settlement. On November 25, 2021, the settlement was established through a judgment of expediency, thus resolving the dispute once and for all.

From a legal and financial perspective, the supplier has agreed to drop all financial claims against Emotra AB and both parties have agreed to pay their own legal costs.

Given the above circumstances, the above-stated provision in Emotra AB's accounting has now been reverted as a cost reduction. This reversal does not affect the company's liquidity.

For further information about Emotra, please contact:

Daniel Poté, President, telephone: +46 73 234 41 93, E-mail: daniel@emotra.se daniel@emotra.se

Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of mental health. The Company's method, EDOR®, is a proprietary and objective psychophysiological test for identifying hyporeactive patients.